- Home
- CAPR vs MOV Comparison
CAPR vs MOV Comparison
Compare CAPR & MOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MOV
- Stock Information
- Founded
- CAPR 2005
- MOV 1961
- Country
- CAPR United States
- MOV United States
- Employees
- CAPR N/A
- MOV N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MOV Consumer Specialties
- Sector
- CAPR Health Care
- MOV Consumer Discretionary
- Exchange
- CAPR Nasdaq
- MOV Nasdaq
- Market Cap
- CAPR 324.6M
- MOV 339.1M
- IPO Year
- CAPR N/A
- MOV 1993
- Fundamental
- Price
- CAPR $6.36
- MOV $19.77
- Analyst Decision
- CAPR Strong Buy
- MOV Strong Buy
- Analyst Count
- CAPR 8
- MOV 1
- Target Price
- CAPR $24.75
- MOV $31.50
- AVG Volume (30 Days)
- CAPR 1.2M
- MOV 181.8K
- Earning Date
- CAPR 11-12-2025
- MOV 08-28-2025
- Dividend Yield
- CAPR N/A
- MOV 7.07%
- EPS Growth
- CAPR N/A
- MOV N/A
- EPS
- CAPR N/A
- MOV 0.77
- Revenue
- CAPR $13,392,150.00
- MOV $655,597,000.00
- Revenue This Year
- CAPR N/A
- MOV $0.71
- Revenue Next Year
- CAPR $6,061.53
- MOV N/A
- P/E Ratio
- CAPR N/A
- MOV $25.68
- Revenue Growth
- CAPR N/A
- MOV 0.79
- 52 Week Low
- CAPR $4.05
- MOV $12.85
- 52 Week High
- CAPR $23.40
- MOV $22.20
- Technical
- Relative Strength Index (RSI)
- CAPR 42.32
- MOV 74.81
- Support Level
- CAPR $6.05
- MOV $18.52
- Resistance Level
- CAPR $6.62
- MOV $19.91
- Average True Range (ATR)
- CAPR 0.39
- MOV 0.54
- MACD
- CAPR 0.05
- MOV 0.15
- Stochastic Oscillator
- CAPR 47.89
- MOV 95.57
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.